Clinical and Biochemical Evaluation of 1% Metformin in Non-surgical Treatment of Periodontitis

Clinical and Biochemical Evaluation of the Use of Locally Delivered Metformin as an Adjunctive Therapy to Non Surgical Periodontal Treatment of Periodontitis Patients (Randomized Controlled Study)

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06204185

Enrollment

Registered

2024-01-12

Start date

2019-02-01

Completion date

2022-11-30

Last updated

2024-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis

Brief summary

The aim of the study to evaluate the clinical and biochemical efficacy of 1% Metformin gel in treatment of periodontitis patients

Interventions

DRUGMetformin

Locally delivered Metformin gel in the treatment of periodontitis patients

DRUGPlacebo

Placebo gel consist of drug without the active component.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Intervention model description

Evaluate the clinical parameters ( Probing Depth, Clinical Attachment Level, Gingival and Plaque Indices) before & after the application of locally delivered metformin as an adjunctive therapy to non surgical periodontal treatment of Stage III periodontitis.

Eligibility

Sex/Gender

ALL

Age

30 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients with Stage III Grade A Periodontitis. * Systemically free according to the modified Burkitt's health history questionnaire, Group I. (Glick et al., 2021). * Good compliance with the plaque control instructions following initial therapy. * Availability for follow up and maintenance program.

Exclusion criteria

* Smokers * Pregnant and lactating females. * Vulnerable groups of patients' e.g (prisoners, handicapped patients and decisionally impaired individuals).

Design outcomes

Primary

Measure	Time frame
RANKL and Osteoprotegrin levels in Gingival Crevicular Fluid before & after application of metformin as an adjunctive therapy to non surgical periodontal treatment of Stage III periodontitis.	Baseline and 1 month after the gel application

Secondary

Measure	Time frame
Plaque index (PI)	Baseline, 3 Months and 6 Months post operatively.
Gingival Index (GI)	Baseline, 3 Months and 6 Months post operatively.
Probing depth (PD)	Baseline, 3 Months and 6 Months post operatively.
Clinical attachment level (CAL)	Baseline, 3 Months and 6 Months post operatively.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026